Katelaris Peter, Naganathan Vasi, Liu Ken, Krassas George, Gullotta John
Gastroenterology Department, Concord Hospital, The University of Sydney, Hospital Rd, Concord, NSW, Australia.
Centre for Education and Research on Ageing and The Ageing and Alzheimers Institute, University of Sydney and Concord Hospital, Hospital Rd, Concord, NSW, Australia.
BMC Gastroenterol. 2016 Mar 31;16:42. doi: 10.1186/s12876-016-0457-9.
Polyethylene glycol is commonly used to manage constipation and is available with or without electrolytes. The addition of electrolytes dates back to its initial development as lavage solutions in preparation for gastrointestinal interventions. The clinical utility of the addition of electrolytes to polyethylene glycol for the management of constipation is not established. The objective of this systematic review and network meta-analysis (NMA) was to assess the relative effectiveness of polyethylene glycol with (PEG + E) or without electrolytes (PEG) in the management of functional constipation in adults.
A systematic review was conducted to identify randomised controlled clinical trials that assessed the use of polyethylene glycol in functional constipation. The primary outcome was the mean number of bowel movements per week.
Nineteen studies were included in the NMA (PEG N = 9, PEG + E N = 8, PEG versus PEG + E N = 2; involving 2247 patients). PEG and PEG + E are both effective, increasing the number of bowel movements per week by 1.8 (95 % Crl 1.0, 2.8) and 1.9 (95 % Crl 0.9, 3.0) respectively versus placebo and by 1.8 (95 % Crl 0.0, 3.5) and 1.9 (95 % Crl 0.2, 3.6) respectively versus lactulose. There was no efficacy difference between PEG + E and PEG (0.1, 95 % Crl -1.1, 1.2) and there were no differences in safety or tolerability.
Polyethylene glycol with and without electrolytes are effective and safe treatments for constipation in adults. The addition of electrolytes to polyethylene glycol does not appear to offer any clinical benefits over polyethylene glycol alone in the management of constipation.
聚乙二醇常用于治疗便秘,有含电解质和不含电解质两种剂型。添加电解质可追溯到其最初作为胃肠道干预术前灌洗溶液的研发阶段。聚乙二醇添加电解质治疗便秘的临床效用尚未确立。本系统评价和网状Meta分析(NMA)的目的是评估含电解质聚乙二醇(PEG + E)和不含电解质聚乙二醇(PEG)治疗成人功能性便秘的相对有效性。
进行系统评价以识别评估聚乙二醇治疗功能性便秘的随机对照临床试验。主要结局是每周平均排便次数。
NMA纳入了19项研究(PEG组n = 9,PEG + E组n = 8,PEG与PEG + E对比组n = 2;涉及2247例患者)。PEG和PEG + E均有效,与安慰剂相比,每周排便次数分别增加1.8次(95%可信区间1.0,2.8)和1.9次(95%可信区间0.9,3.0);与乳果糖相比,每周排便次数分别增加1.8次(95%可信区间0.0,3.5)和1.9次(95%可信区间0.2,3.6)。PEG + E与PEG之间无疗效差异(0.1,95%可信区间 -1.1,1.2),安全性和耐受性方面也无差异。
含电解质和不含电解质的聚乙二醇都是治疗成人便秘的有效且安全的方法。在便秘治疗中,聚乙二醇添加电解质似乎并不比单用聚乙二醇有任何临床优势。